Compare HKPD & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | CODX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 15.6M |
| IPO Year | 2025 | 2017 |
| Metric | HKPD | CODX |
|---|---|---|
| Price | $0.74 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 129.4K | ★ 1.5M |
| Earning Date | 08-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,313,818.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.72 | N/A |
| 52 Week Low | $0.72 | $0.23 |
| 52 Week High | $3.79 | $1.55 |
| Indicator | HKPD | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 27.59 | 46.20 |
| Support Level | $0.76 | $0.34 |
| Resistance Level | $0.86 | $0.41 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.80 | 22.21 |
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.